Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Common Equity (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Common Equity readings, the most recent being $274.2 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 41.33% to $274.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $274.2 million, a 41.33% increase, with the full-year FY2025 number at $274.2 million, up 41.33% from a year prior.
  • Common Equity hit $274.2 million in Q4 2025 for Amicus Therapeutics, up from $230.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $376.6 million in Q3 2021 to a low of $102.6 million in Q1 2023.
  • Median Common Equity over the past 5 years was $186.2 million (2024), compared with a mean of $193.1 million.
  • Biggest five-year swings in Common Equity: plummeted 64.8% in 2022 and later surged 54.16% in 2025.
  • Amicus Therapeutics' Common Equity stood at $307.4 million in 2021, then plummeted by 59.97% to $123.0 million in 2022, then surged by 30.17% to $160.2 million in 2023, then increased by 21.15% to $194.0 million in 2024, then soared by 41.33% to $274.2 million in 2025.
  • The last three reported values for Common Equity were $274.2 million (Q4 2025), $230.4 million (Q3 2025), and $204.3 million (Q2 2025) per Business Quant data.